- Home
- SPRO vs RDI Comparison
SPRO vs RDI Comparison
Compare SPRO & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- RDI
- Stock Information
- Founded
- SPRO 2013
- RDI 1937
- Country
- SPRO United States
- RDI United States
- Employees
- SPRO N/A
- RDI N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- RDI Movies/Entertainment
- Sector
- SPRO Health Care
- RDI Consumer Discretionary
- Exchange
- SPRO Nasdaq
- RDI Nasdaq
- Market Cap
- SPRO 33.0M
- RDI 30.1M
- IPO Year
- SPRO 2017
- RDI N/A
- Fundamental
- Price
- SPRO $2.50
- RDI $1.38
- Analyst Decision
- SPRO Buy
- RDI Hold
- Analyst Count
- SPRO 4
- RDI 1
- Target Price
- SPRO $5.00
- RDI $2.40
- AVG Volume (30 Days)
- SPRO 10.8M
- RDI 38.2K
- Earning Date
- SPRO 05-13-2025
- RDI 05-15-2025
- Dividend Yield
- SPRO N/A
- RDI N/A
- EPS Growth
- SPRO N/A
- RDI N/A
- EPS
- SPRO N/A
- RDI N/A
- Revenue
- SPRO $44,584,000.00
- RDI $205,644,000.00
- Revenue This Year
- SPRO N/A
- RDI $9.74
- Revenue Next Year
- SPRO N/A
- RDI $6.39
- P/E Ratio
- SPRO N/A
- RDI N/A
- Revenue Growth
- SPRO N/A
- RDI N/A
- 52 Week Low
- SPRO $0.51
- RDI $1.17
- 52 Week High
- SPRO $2.80
- RDI $1.89
- Technical
- Relative Strength Index (RSI)
- SPRO 86.18
- RDI 52.10
- Support Level
- SPRO $0.66
- RDI $1.34
- Resistance Level
- SPRO $2.48
- RDI $1.49
- Average True Range (ATR)
- SPRO 0.13
- RDI 0.08
- MACD
- SPRO 0.20
- RDI 0.00
- Stochastic Oscillator
- SPRO 86.36
- RDI 32.35
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.